Want to see SEPN full AI Analyst Report?
Top Page
Septerna, Inc.
(NASDAQ:SEPN)
Select Model
Select Model
Rating:57Neutral
Price Target:
$36.00
▲(37.77% Upside)
Action:Reiterated
Date:06/30/26
The score is mainly driven by improving fundamentals—sharp revenue growth, strong positive operating/free cash flow, and a conservatively levered balance sheet—offset by continued operating losses and negative returns on equity. Lack of technical indicator data limits confidence in near-term trend assessment, while valuation is constrained by a negative P/E and missing dividend yield. Corporate events provide a modest positive tailwind from Phase 1 trial progress and stable governance.
Positive Factors
Revenue Growth
Sustained, sharp revenue growth across 2025 and TTM 2026 indicates improving commercial traction or successful monetization of programs. Over the next 2–6 months this momentum supports scaling, reduces near-term funding reliance, and strengthens bargaining power with partners and suppliers.
Negative Factors
Negative Operating Margins
Persistent sizable operating losses mean the business is not yet self-sustaining from operations. Even with revenue growth, ongoing negative margins will require sustained cash or external financing, constraining capital allocation and limiting long-term profitability until costs scale or revenues increase further.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, sharp revenue growth across 2025 and TTM 2026 indicates improving commercial traction or successful monetization of programs. Over the next 2–6 months this momentum supports scaling, reduces near-term funding reliance, and strengthens bargaining power with partners and suppliers.
Read all positive factors
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.53B
Dividend YieldN/A
Average Volume (3M)320.59K
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue Growth7295.60%
EPS Growth58.57%
CountryUS
Employees130
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume315,821
30 Day Avg. Volume320,586
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue21.66
Enterprise Value/Gross Profit21.79
Enterprise Value/Ebitda-30.03
Forecast
1Y Price Target
$47.43Price Target Upside81.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$76.98M
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1...
How the Company Makes Money
null...
Septerna, Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.25M | 45.95M | 1.07M | 151.00K | 0.00 |
| Gross Profit | 71.83M | 45.95M | 1.07M | 151.00K | 0.00 |
| EBITDA | -52.12M | -47.26M | -70.89M | -44.70M | -27.39M |
| Net Income | -36.04M | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | |||||
| Total Assets | 569.69M | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 347.40M | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 23.09M | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 191.23M | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 378.46M | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | |||||
| Free Cash Flow | 106.93M | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | 107.90M | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -248.29M | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 1.96M | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Neutral
26.13
Price Trends
29.57
Positive
27.88
Positive
25.70
Positive
Market Momentum
1.45
Positive
53.27
Neutral
33.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Neutral. The current price of 26.13 is below the 20-day moving average (MA) of 34.19, below the 50-day MA of 29.57, and above the 200-day MA of 25.70, indicating a neutral trend. The MACD of 1.45 indicates Positive momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 33.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Septerna, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $877.45M | 7.48 | 43.85% | ― | 68.20% | ― | |
65 Neutral | $1.56B | -8.33 | -44.72% | ― | -15.35% | 37.09% | |
57 Neutral | $1.53B | -41.98 | -9.44% | ― | 7295.60% | 58.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $985.40M | -3.31 | -141.95% | ― | 5.37% | -60.20% | |
43 Neutral | $84.67M | -0.22 | 174.85% | ― | -55.42% | -248.85% |
* General Sector Average
SEPN
Septerna, Inc.
34.00
23.15
213.36%
TBPH
Theravance Biopharma
16.93
5.62
49.69%
KURA
Kura Oncology
11.10
5.42
95.42%
GOSS
Gossamer Bio
0.17
-1.08
-86.16%
MRVI
Maravai Lifesciences Holdings
6.04
3.44
132.31%
Septerna, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Septerna Shareholders Elect Directors, Ratify Ernst & Young
Positive
Jun 30, 2026
At its annual meeting of stockholders held on June 26, 2026, Septerna, Inc. reported that shareholders elected Shalini Sharp and Jake Simson as Class II directors to the Board for three‑year terms ending in 2029, with both to serve until suc...
Business Operations and StrategyProduct-Related Announcements
Septerna Begins Phase 1 Trial of Oral SEP-479
Positive
Apr 13, 2026
On April 13, 2026, Septerna, Inc. reported that it has begun dosing participants in a Phase 1 clinical trial of SEP-479, an oral small molecule parathyroid hormone 1 receptor agonist being developed to treat hypoparathyroidism. The program targets...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.